Aditxt Inc

NASDAQ:ADTXUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.

Contact Information

Headquarters

737 N. Fifth Street, Suite 200RICHMOND, VA, United States 23219

Phone

909-488-0844

Fax

302-697-4597

Executives

Chairman of the Board, Chief Executive Officer

Amro Albanna

Chief Financial Officer

Thomas Farley

Chief Operating Officer

Rowena Albanna

Chief Innovation Officer, Director

Shahrokh Shabahang

Chief Mergers & Acquisitions Officer

Corinne Pankovcin